Skip to content

Adarx Pharmaceuticals

US · ADRX #2823 by market cap Listed 2026
12.79 -1.37 -9.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 14.32 +1.13%
After-hours 12.79 0.00%
20.6412.7912.792026-09-252026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ADRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Main-fund capital flow has been a net inflow over the last 36 sessions.
  • Short interest has risen to 1.8% of float.
  • Analyst tilt is Buy.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Key statistics

Price & volume

Prev close
14.16
Open
14.03
Day range
12.63 - 14.87
Avg price
13.57
Volume
708.83K
Turnover
9.62M
Amplitude
15.82%
52-week range
12.50 - 23.21

Valuation

P/E
-13.19
P/E (TTM)
-13.98
P/B
2.48
EPS
-0.97
Net profit
-107.86M
Net assets
574.43M

Share structure

Market cap
1.42B
Float cap
279.78M
Shares out
111.19M
Float shares
21.88M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-09-25
52-week range 3% of range
12.50 23.21

44.9% below the 52-week high

Trading activity

Net capital flow main funds, last 36 sessions

+147.92K net over the window

Short interest

Shares short
1.80M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Adarx Pharmaceuticals (ADRX)?

Adarx Pharmaceuticals last traded at 12.79. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Adarx Pharmaceuticals's market cap?

About 1.42B.

What is the P/E ratio of Adarx Pharmaceuticals?

The trailing twelve-month P/E is -13.98. The Valuation tab shows it against the stock's own five-year range.

Does Adarx Pharmaceuticals pay a dividend?

Adarx Pharmaceuticals does not currently pay a regular dividend.

Is Adarx Pharmaceuticals a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 35.00, which implies 173.7% upside from the current price. This is not investment advice.

What is Adarx Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Adarx Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adarx Pharmaceuticals discussion 0 comments

Add a comment